Immunomedics Inc. on Wednesday said it has received orphandrug designation from the FDA for its ImmuRAID-LL2 imagingagent.

The imaging agent is in Phase I/II trials for non-Hodgkin's B-cell lymphomas. The orphan designation also applies to imagingof acute B-cell lymphoblastic leukemia and chronic B-celllymphocytic leukemia, the Warren, N.J., company said. Theagent consists of a monoclonal antibody fragment attached totechnetium-99m radioisotope.

The stock (NASDAQ:IMMU) lost 25 cents to $9.88 onWednesday.

(c) 1997 American Health Consultants. All rights reserved.